Galmed Pharmaceuticals
GLMD
22 hedge funds and large institutions have $11.8M invested in Galmed Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 22 → 22 (0)
0% less ownership
Funds ownership: 0.01% → 0.01% (-0%)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
19% less capital invested
Capital invested by funds: $14.6M → $11.8M (-$2.83M)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
84% less call options, than puts
Call options by funds: $80K | Put options by funds: $504K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TI
Tidal Investments
Milwaukee,
Wisconsin
|
+$71.3K |
| 2 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$62.9K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$62.9K |
| 4 |
Millennium Management
New York
|
+$37.8K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$21K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$1.66M |
| 2 |
II
Ibex Investors
Denver,
Colorado
|
-$79.7K |
| 3 |
Morgan Stanley
New York
|
-$58.7K |
| 4 |
JF
Jump Financial
Chicago,
Illinois
|
-$51K |
| 5 |
Two Sigma Advisers
New York
|
-$46K |
GLMD Hedge Fund Activity: Q3 2021 in Review
22 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q3 2021, worth a combined $11.8M — down 19% from $14.6M a quarter earlier.
Fund positioning in GLMD was balanced in Q3 2021: 3 funds opened new positions, 3 closed out, 4 added to existing stakes and 5 trimmed.
The largest buyer was Tidal Investments, opening a new position worth an estimated $71.3K. The largest seller was Nantahala Capital Management, cutting an estimated $1.66M.
- 22 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q3 2021, unchanged from Q2 2021.
- Funds reported $11.8M of Galmed Pharmaceuticals stock for Q3 2021, down 19% quarter-over-quarter.
- 3 funds opened new Galmed Pharmaceuticals positions in Q3 2021 and 3 closed out, a net change of 0 holders.
- The largest Galmed Pharmaceuticals buyer in Q3 2021 was Tidal Investments, an estimated $71.3K added.
- The largest Galmed Pharmaceuticals seller in Q3 2021 was Nantahala Capital Management, an estimated $1.66M sold.
Based on aggregated 13F filings for Q3 2021.